Kainos Laboratories, Inc. (4556) AI Stock Analysis

• Market Cap: ¥9.33B
• Dividend Yield: 2.53%
• Average Volume (3M): 3.67K
• Price to Earnings (P/E): 16.1
• Beta (1Y): 0.55
• Revenue Growth: 3.14%
• EPS Growth: -2.85%
• Country: JP
• Employees: 133
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 105.98
• Shares Outstanding: 4,558,860
• 10 Day Avg. Volume: 3,280
• 30 Day Avg. Volume: 3,666
• PEG Ratio: -62.73
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 1.00
• P/FCF Ratio: 8.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 85 Outperform
• Price Target: ¥2,677.00 ▲(110.62% Upside)
• Action: Upgraded Date: 02/10/26
• Date: Action: Upgraded 02/10/26

The score is driven primarily by strong financial performance (profitability, low leverage, and especially strong free cash flow growth) and an attractive valuation (low P/E with a solid dividend yield). Technicals are supportive due to a strong uptrend, but the very high RSI suggests the stock may be overextended in the near term, moderating the overall score.

Positive Factors

High profit margins

Sustained, high gross and operating margins indicate the company captures value from its diagnostic reagents business. Durable margins support reinvestment in R&D and operations, improving resilience to price pressure and enabling consistent operating cash generation over the medium term.

Conservative balance sheet

Very low leverage and a high equity ratio provide structural financial flexibility. This balance sheet strength reduces refinancing risk, supports capital allocation for growth or M&A, and helps the company withstand industry cyclicality without eroding operational capacity.

Strong cash generation

Exceptional free cash flow growth and near parity of FCF to net income show efficient conversion of earnings to cash. Durable cash generation underpins funding for capex, dividends, or strategic investment without reliance on external debt, enhancing long-term financial independence.

Negative Factors

Modest revenue growth

Revenue expansion is positive but relatively low for a life‑sciences diagnostics firm. Slower top-line growth can limit scale advantages, reduce the pace of margin improvement, and constrain absolute earnings growth absent new product launches or market expansion initiatives.

Moderate return on equity

An ROE below double digits suggests the company generates modest returns on shareholders' capital. Over time this can limit compounding of shareholder value versus higher‑return peers and may require either faster growth or improved capital efficiency to boost long‑term investor returns.

Limited organizational scale

A small workforce indicates limited internal scale for commercial expansion, regulatory work, and parallel product development. Structurally this can slow market penetration and prolong time to scale in new geographies or assays versus larger competitors with deeper organizational resources.

Kainos Laboratories, Inc. Business Overview & Revenue Model

Company Description

KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company offers point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Kainos Laboratories generates revenue through multiple key streams, primarily by selling its proprietary diagnostic tests and medical devices to hospitals, clinics, and laboratories. The company also engages in partnerships with pharmaceutical companies for the development of companion diagnostics, which are essential for personalized medicine. Additionally, Kainos Laboratories may earn income through research grants and collaborations with academic institutions, further expanding its product portfolio and market reach. Significant revenue is driven by the adoption of its technologies in clinical settings, alongside recurring revenue from ongoing service contracts and maintenance of diagnostic equipment.

Kainos Laboratories, Inc. Financial Statement Overview

Summary

Strong fundamentals across statements: solid profitability (gross margin 49.28%, net margin 12.08%) and healthy operating efficiency (EBITDA margin 17.66%). Balance sheet is conservative (debt-to-equity 0.09; equity ratio 77.12%). Cash generation is a standout with free cash flow growth of 78.44% and good earnings-to-cash conversion (OCF/NI 1.10; FCF/NI 0.99).

Income Statement

Kainos Laboratories has demonstrated consistent revenue growth with a Revenue Growth Rate of 4.93% from 2024 to 2025. The Gross Profit Margin is 49.28% for 2025, indicating strong profitability. The Net Profit Margin has improved to 12.08%, reflecting efficient cost management. EBIT and EBITDA margins are robust at 15.52% and 17.66%, respectively, highlighting the company's operational efficiency.

Balance Sheet

The company maintains a strong financial position with a low Debt-to-Equity Ratio of 0.09, indicating conservative leverage. The Equity Ratio is high at 77.12%, showing a strong capital structure. Return on Equity (ROE) is healthy at 9.46%, reflecting effective use of equity capital to generate profits.

Cash Flow

Kainos Laboratories exhibits strong cash flow performance with a Free Cash Flow Growth Rate of 78.44% from 2024 to 2025. The Operating Cash Flow to Net Income Ratio is favorable at 1.10. The Free Cash Flow to Net Income Ratio stands at 0.99, indicating efficient conversion of earnings into free cash flow.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	5.31B	5.06B	4.92B	4.61B	4.26B
Gross Profit	2.61B	2.55B	2.51B	2.41B	2.31B
EBITDA	936.87M	1.05B	994.26M	924.87M	763.42M
Net Income	641.02M	637.97M	568.17M	512.33M	417.40M
Balance Sheet
Total Assets	8.79B	8.59B	8.12B	7.57B	6.96B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.17B	3.02B	2.68B	2.24B
Total Debt	629.49M	862.97M	941.10M	947.61M	1.00B
Total Liabilities	2.01B	2.32B	2.45B	2.37B	2.30B
Stockholders Equity	6.78B	6.27B	5.67B	5.20B	4.66B
Cash Flow
Free Cash Flow	633.30M	354.87M	536.81M	463.19M	518.06M
Operating Cash Flow	704.78M	430.58M	544.51M	604.36M	591.25M
Investing Cash Flow	-71.30M	-72.83M	-10.33M	-141.19M	-117.16M
Financing Cash Flow	-411.04M	-203.73M	-191.14M	-31.25M	-194.61M

Kainos Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1271.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Positive. The current price of 1271 is below the 20-day moving average (MA) of 1972.35, below the 50-day MA of 1573.62, and below the 200-day MA of 1336.38, indicating a bullish trend. The MACD of 238.70 indicates Negative momentum. The RSI at 94.64 is Negative, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4556.

Kainos Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4556	85 Outperform	¥9.33B	16.07	―	2.53%	3.14%	-2.85%
4543	69 Neutral	¥3.12T	24.33	9.31%	1.22%	7.68%	10.08%
7747	68 Neutral	¥893.08B	50.74	10.09%	0.82%	13.53%	-7.39%
6869	68 Neutral	¥917.95B	20.51	9.80%	1.88%	1.51%	-12.59%
8086	62 Neutral	¥259.41B	17.06	4.38%	2.03%	6.04%	733.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%